Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human YWHAE ELISA Kit (AC2750)
Cat.#: ASET-1339
Specifications
Description Human YWHAE ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human YWHAE concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 14.77 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 300-4800 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1954 Rat Progesterone Receptor ELISA Kit (AC3365) Quantitative inquiry ASET-1218 Rat GAPDH ELISA Kit (AC2629) Quantitative inquiry ASET-1222 Human PDE7B ELISA Kit (AC2633) Quantitative inquiry ASET-1343 Human Netrin 4 ELISA Kit (AC2754) Quantitative inquiry ASET-1788 Human MAN2B1 ELISA Kit (AC3199) Quantitative inquiry ASET-1964 Human Prol1 ELISA Kit (AC3375) Quantitative inquiry ASET-1686 Human LRP5 ELISA Kit (AC3097) Quantitative inquiry ASET-1101 Human RDH11 ELISA Kit (AC2512) Quantitative inquiry ASET-1580 Human ANGPTL7 ELISA Kit (AC2991) Quantitative inquiry ASET-2025 Human HNT ELISA Kit (AC3436) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket